Boehringer beats Bayer to the regulators
The FDA will rule on a low dose of zongertinib in the summer.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
Avenzo follows Bristol’s lead
The private group taps DualityBio for an EGFR x HER3 ADC.
Affimed needs more time with AFM24
Data deteriorate, leaving cash-strapped Affimed relying on a post-hoc analysis and higher dosing.
The month ahead: December’s upcoming events
Party season approaches; but first, conferences.
